CClinicalTrials.gg
CompletedNCT06709261FORTEUpdated Aug 31, 2026

Safety and Performance of the OTTAVA Robotic System

An interventional study of OTTAVA Robotic System in Obesity, sponsored by Auris Health, Inc.. Completed at 6 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Auris Health, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

This study assesses safety and performance of the OTTAVA Robotic System, through 30 days postoperative, in subjects undergoing robotic-assisted Roux-en-Y Gastric Bypass (RYGB) procedure.

02

Conditions studied

  • Obesity

Browse trials for

03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Criteria for Inclusion:

  1. Willing and able to provide informed consent;
  2. Scheduled for an elective primary RYGB surgical procedure;
  3. American Society of Anesthesiologists classification ≤ ASA III;
  4. Body habitus such that the procedure can be safely completed with OTTAVA Robotic System;
  5. Body weight \<500 lb (227 kg);
  6. Patient presenting with class 2 or 3 obesity (BMI ≥ 35), regardless of comorbidities, or obesity with health risk satisfying 2022 ASMBS/IFSO indications for bariatric surgery; and
  7. A minimum of 21 years of age (at time of consent).

Criteria for Exclusion:

  1. Surgeon determination that there is a medical condition, that makes surgery too risky, including intraoperative finding;
  2. Concomitant surgical procedure including cholecystectomy (hiatal hernia repair up to 5 cm and adhesiolysis allowed);
  3. Upper abdominal surgery within two years prior to enrollment (prior laparoscopic cholecystectomy allowed);
  4. Evidence of hiatal hernia >5 cm (preoperative/intraoperative);
  5. Enrolled in another investigational study that may confound the results of this study;
  6. Emergency surgery;
  7. Active pregnancy; or
  8. Subject from a vulnerable population, including anyone unable to adequately provide informed consent.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    OTTAVA Robotic System

    Procedure with the OTTAVA Robotic System

    Device: OTTAVA Robotic System

Interventions

  • DeviceOTTAVA Robotic System

    Procedure with the OTTAVA Robotic System

05

What researchers measure

Primary outcomes

  1. Procedure completion without conversion to open surgery

    Time frame: Procedure day

  2. Occurrence of intraoperative and postoperative device- or procedure-related complications

    Time frame: Through 30 days post-procedure

Secondary outcomes

  1. Occurrence of all adverse events

    Time frame: Through 30 days post-procedure

  2. Total operative time

    Time frame: Procedure day

  3. Estimated blood loss

    Time frame: Procedure day

  4. Occurrence of blood transfusion

    Time frame: Procedure day

  5. Device malfunction details

    Time frame: Procedure day

  6. Length of hospital stay

    Time frame: Hospital stay, assessed up to 30 days

  7. Hospital readmission

    Time frame: Through 30 days

  8. Reoperation

    Time frame: Through 30 days

  9. Anastomotic leak

    Time frame: Through 30 days

  10. Anastomotic stricture

    Time frame: Through 30 days

  11. Mortality

    Time frame: Through 30 days

06

Study locations

6 sites
  • Orlando Health
    Orlando, Florida 32806, United States
  • University of South Florida Tampa General Hospital
    Tampa, Florida 33606, United States
  • IU Health North Hospital
    Indianapolis, Indiana 46302, United States
  • NYU Long Island
    Mineola, New York 11501, United States
  • Duke Regional Hospital
    Durham, North Carolina 27704, United States
  • UT Health Houston and Memorial Hermann TMC
    Bellaire, Texas 77401, United States
07

Registry details

Key details

Study ID
NCT06709261
Lead sponsor
Auris Health, Inc.
Responsible party
Sponsor
First posted
Nov 29, 2024
Start date
Feb 5, 2025
Primary completion
Oct 20, 2025
Completion
Oct 20, 2025
Last update
Aug 31, 2026

Study contacts

Erik Wilson, MD
principal investigator · Memorial Hermann Texas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion